These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo. He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832 [TBL] [Abstract][Full Text] [Related]
3. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430 [TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Kievit FM; Wang K; Ozawa T; Tarudji AW; Silber JR; Holland EC; Ellenbogen RG; Zhang M Nanomedicine; 2017 Oct; 13(7):2131-2139. PubMed ID: 28614736 [TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419 [TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
8. Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG Man RCH; Qiu Y; Leung SWS; Fruhwirth GO; Lam JKW Eur J Pharm Biopharm; 2024 Feb; 195():114177. PubMed ID: 38185193 [TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. Varshosaz J; Farzan M World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089 [TBL] [Abstract][Full Text] [Related]
10. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma. Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337 [TBL] [Abstract][Full Text] [Related]
11. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175 [TBL] [Abstract][Full Text] [Related]
12. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522 [TBL] [Abstract][Full Text] [Related]
13. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800 [TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Ene CI; Kreuser SA; Jung M; Zhang H; Arora S; White Moyes K; Szulzewsky F; Barber J; Cimino PJ; Wirsching HG; Patel A; Kong P; Woodiwiss TR; Durfy SJ; Houghton AM; Pierce RH; Parney IF; Crane CA; Holland EC Neuro Oncol; 2020 May; 22(5):639-651. PubMed ID: 31793634 [TBL] [Abstract][Full Text] [Related]
15. EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. Li Y; Du Y; Liang X; Sun T; Xue H; Tian J; Jin Z Nanoscale; 2018 Sep; 10(35):16738-16749. PubMed ID: 30156250 [TBL] [Abstract][Full Text] [Related]
16. An Engineered Nanoplatform with Tropism Toward Irradiated Glioblastoma Augments Its Radioimmunotherapy Efficacy. Wang Z; Chen F; Cao Y; Zhang F; Sun L; Yang C; Xie X; Wu Z; Sun M; Ma F; Shao D; Leong KW; Pei R Adv Mater; 2024 Aug; 36(32):e2314197. PubMed ID: 38713519 [TBL] [Abstract][Full Text] [Related]
17. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy. Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271 [TBL] [Abstract][Full Text] [Related]
18. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077 [TBL] [Abstract][Full Text] [Related]
19. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines. Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032 [TBL] [Abstract][Full Text] [Related]
20. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Hadjipanayis CG; Machaidze R; Kaluzova M; Wang L; Schuette AJ; Chen H; Wu X; Mao H Cancer Res; 2010 Aug; 70(15):6303-12. PubMed ID: 20647323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]